David Bernstein, MD

Director, Sandra Atlas Bass Center for Liver Diseases, The Feinstein Institute for Medical Research

Chief, Division of Hepatology, Northwell Health

Professor, Medicine and Education, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell

Phone: (516) 562-4664
Email: dbernste@northwell.edu

About the Investigator

Dr. Bernstein’s main research interest has been in field of liver diseases, with most of his work concentrated on developing new treatments for chronic hepatitis C. Since 1994, he has been involved in designing programs for the treatment of hepatitis C and has been an influential national and international leader in this field. He is the author of over 100 publications, 10 book chapters, and has been the principle investigator in more than 200 clinical trials. His work has been published in such prestigious journals as the New England Journal of Medicine and The Lancet. He regularly is asked to lecture about this topic on Long Island, across the nation and around the globe. His research has led to the development of new medications which are able to cure more than 95% of patients with hepatitis C infection and in the future could lead to the eradication of hepatitis C infection in the United States.

Dr. Bernstein is active in many national and international societies and has held elective office in many of them. He is the current President of the Bockus International Society of Gastroenterology and a former president of the New York Gastrointestinal Society. He served for six years as the American College of Gastroenterology Governor for Long Island. He has served on numerous committees of the American Association for the Study of Liver Diseases and the American College of Gastroenterology. He is also a member of the European Society for the Study of Liver Diseases, the Asia-Pacific Association for the Study of Liver Diseases. He is a fellow of the American Association for the Study of Liver Diseases, the American College of Gastroenterology and the American College of Physicians.

Dr. Bernstein has been involved in shaping public policy and education regarding liver diseases. He serves as a special consultant to the New York State Department of Health and in that role has helped develop and implement New York State’s 5-year Strategic Plan for Viral Hepatitis as well as lead the group developing guidelines to be used for the treatment of hepatitis C in New York State. He regularly leads telemedicine conferences for public health providers, prison health providers and federally qualified health care centers to educate these providers and has made himself available as a special consultant to these centers for individual cases questions.

Research Focus

Viral hepatitis; Nonalcoholic fatty liver disease; Primary biliary cholangitis; Autoimmune liver disease; Liver cancer; Cirrhosis; Outcomes in liver disease; Access to care and public policy

Education

University of Miami Affiliated Hospitals
Degree: Fellowship
Field of Study: Hepatology

University of Miami Affiliated Hospitals
Degree: Fellowship
Field of Study: Gastroenterology

Montefiore Medical School
Degree: Medical Residency

Montefiore Medical School
Degree: Medical Internship

SUNY-Stony Brook School of Medicine

Honors and Awards

2015-2019 GlaxoSmithKline IIS

Publications
  1. Ferenci P, Bernstein DE, Lalezari J, Cohen D, Luo Y, Cooper C, Tam E, Tsao N, Nyberg A, Box T, Younes Z, Green S, Baruch Y, Bhardari B, Catuntu F, Sepe T, Chulanov V, Janczewska E, Rizzardini G, Gervath J, Pianas R, Moreno C, Hassanein T, Xie W, King M, Podsadecki T, Reddy KR. “ABT-450/r-Ombitasvir and dasabuvir with or without ribavirin for HCV.” NEJM 2014; 370; 1983-1992
  2. Kowdley K, Gordon S, Reddy K, Rossaro L, Bernstein D, Lawitz E, Shiffman M, Schiff E,  Ghalib R, Ryan M, Rustgi V, Chojkier M, Herring R, Di Bisceglie A, Pockros P, Subramanian M, Svarovskaia E, Hyland R, Pang P, Symonds W, McHutchison J, Muir A, Pound D, Fried M. “Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis.” NEJM 2014; 370:1879-1888
  3. Kowdley KV, Lawitz E, Crespo I, Hassanein T, David M, DeMIcco M, Bernstein D, Afdhal N, Vierling JM, Gordon SC, Andeson JK, Hyland RH, Dvory-Sobol H, An D, Hindes RG, Albanis E, Symonds WT, Berrey MM, Nelson DR, Jacobson IM. “Sofosbuvir with pegylated inteferon alfa 2a and ribavirin for treatment naive patients with hepatitis C genotype 1 infection: an open l;abel, randomised multicenter phase 2 trial.” Lancet 2013; 15: 2100-2107
  4. Lawitz E, Lalezari JP, Hassasein T, Kowdley KV, Poordad FF, Sheikh AM, Afdhal NH, Bernstein DE, Dejesus E, Freilich B, Nelson DR, Dieterich DT, Jacobson IM, Jensen D, Abrams GA, Darling JM, Rodriguez-Torres M, Reddy KR, Sulkowski MS, Bzowej NH, Hyland RH, Mo H, Lin M, Mader M, Hindes R, Albanis E, Symonds WT, Berrey MM, Muir A. “Sofosbuvir in combination with peginterferon alfa 2a and ribavirin for non-cirrhotic, treatment naive patients with genotypes 1,2 and 3 hepatitis C infection: a randomised, double blind , phase 2 trial.” Lancet Infectious Disease 2013; 13:401-408.
  5. Satapathy SK, Kim YJ, Kataria A, Shifteh A, Bhansali R, Cerulli M, Bernstein D. “Higher prevalence and more severe coronary artery disease in hepatitis C virus infected patients: A case control study.” Journal of Clinical and Experimental Hepatology 2013;:1-6

View more at PubMed